Exploring direct and indirect targets of current antileishmanial drugs using a novel thermal proteomics profiling
Ana Victoria Ibarra-Meneses1,2, Audrey Corbeil1,2, Victoria Wagner1,2
1Département de Pathologie et Microbiologie, Faculté de Médecine Vétérinaire, Université de Montréal, Saint-Hyacinthe, QC, Canada.
Abstract:
Visceral leishmaniasis (VL), caused by Leishmania infantum, is an oft-fatal neglected tropical disease. In the absence of an effective vaccine, the control of leishmaniasis relies exclusively on chemotherapy. Due to the lack of established molecular/genetic markers denoting parasite resistance, clinical treatment failure is often used as an indicator. Antimony-based drugs have been the standard antileishmanial treatment for more than seven decades, leading to major drug resistance in certain regions. Likewise, drug resistance to miltefosine and amphotericin B continues to spread at alarming rates. In consequence, innovative approaches are needed to accelerate the identification of antimicrobial drug targets and resistance mechanisms. To this end, we have implemented a novel approach based on thermal proteome profiling (TPP) to further characterize the mode of action of antileishmanials antimony, miltefosine and amphotericin B, as well as to better understand the mechanisms of drug resistance deployed by Leishmania. Proteins become more resistant to heat-induced denaturation when complexed with a ligand. In this way, we used multiplexed quantitative mass spectrometry-based proteomics to monitor the melting profile of thousands of expressed soluble proteins in WT, antimony-resistant, miltefosine-resistant, and amphotericin B-resistant L. infantum parasites, in the presence (or absence) of the above-mentioned drugs. Bioinformatics analyses were performed, including data normalization, melting profile fitting, and identification of proteins that underwent changes (fold change > 4) caused by complexation with a drug. With this unique approach, we were able to narrow down the regions of the L. infantum proteome that interact with antimony, miltefosine, and amphotericin B; validating previously-identified and unveiling novel drug targets. Moreover, analyses revealed candidate proteins potentially involved in drug resistance. Interestingly, we detected thermal proximity coaggregation for several proteins belonging to the same metabolic pathway (i.e., tryparedoxin peroxidase and aspartate aminotransferase in proteins exposed to antimony), highlighting the importance of these pathways. Collectively, our results could serve as a jumping-off point for the future development of innovative diagnostic tools for the detection and evaluation of antimicrobial-resistant Leishmania populations, as well as open the door for new on-target therapies.
Insights
Thermal proteome profiling identified new drug targets and resistance mechanisms in Leishmania infantum, crucial for developing novel treatments against visceral leishmaniasis (VL). This approach aids in understanding and combating drug resistance in this fatal neglected tropical disease.
Area of Science:
- Parasitology and Tropical Diseases
- Molecular Biology and Proteomics
- Drug Discovery and Pharmacology
Background:
- Visceral leishmaniasis (VL), caused by Leishmania infantum, is a fatal neglected tropical disease with limited treatment options.
- Current chemotherapy relies on drugs like antimony, miltefosine, and amphotericin B, but widespread drug resistance is a growing concern.
- Lack of molecular markers for resistance necessitates innovative methods to identify drug targets and resistance mechanisms.
Purpose of the Study:
- To characterize the mode of action of antileishmanial drugs (antimony, miltefosine, amphotericin B).
- To understand the mechanisms of drug resistance in Leishmania parasites.
- To identify novel drug targets and proteins involved in antileishmanial drug resistance.
Main Methods:
- Implementation of thermal proteome profiling (TPP), a novel approach utilizing multiplexed quantitative mass spectrometry-based proteomics.
- Monitoring protein melting profiles in wild-type and drug-resistant Leishmania infantum strains in the presence and absence of antileishmanial drugs.
- Bioinformatics analysis including data normalization, melting profile fitting, and identification of drug-protein interactions and resistance-associated proteins.
Main Results:
- TPP successfully narrowed down proteome regions interacting with antimony, miltefosine, and amphotericin B, validating known and uncovering novel drug targets.
- Candidate proteins potentially involved in drug resistance mechanisms were identified.
- Thermal proximity coaggregation analysis highlighted the importance of specific metabolic pathways, such as those involving tryparedoxin peroxidase and aspartate aminotransferase, in antimony response.
Conclusions:
- The study provides a valuable platform for identifying antileishmanial drug targets and understanding resistance mechanisms.
- Results pave the way for developing innovative diagnostic tools for antimicrobial-resistant Leishmania populations.
- The findings open avenues for the development of new on-target therapies to combat visceral leishmaniasis.
Related Concept Videos
Leishmaniasis
Antiprotozoal Agents


